Portal de Periódicos da CAPES

Zaprinast: A cGMP‐Selective Phosphodiesterase Inhibitor

1993; Wiley; Volume: 11; Issue: 4 Linguagem: Inglês

10.1111/j.1527-3466.1993.tb00203.x

1527-3466

Linda Merkel,

Receptor Mechanisms and Signaling

Cardiovascular Drug ReviewsVolume 11, Issue 4 p. 501-515 Free to Read Zaprinast: A cGMP-Selective Phosphodiesterase Inhibitor Linda Merkel, Corresponding Author Linda Merkel Department of Cardiovascular Biology, Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA.Address correspondence and reprint requests to Dr. L. Merkel at Department of Cardiovascular Biology, Rhône-Poulenc Rorer Pharmaceuticals, 500 Arcola Road, P.O. Box 1200, Collegeville, PA 19426-0107, USA.Search for more papers by this author Linda Merkel, Corresponding Author Linda Merkel Department of Cardiovascular Biology, Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA, USA.Address correspondence and reprint requests to Dr. L. Merkel at Department of Cardiovascular Biology, Rhône-Poulenc Rorer Pharmaceuticals, 500 Arcola Road, P.O. Box 1200, Collegeville, PA 19426-0107, USA.Search for more papers by this author First published: December 1993 https://doi.org/10.1111/j.1527-3466.1993.tb00203.xCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 1989; 38: 3331– 3339. 2 Andersson TLG, Vinge E. Interactions between isoprenaline, sodium nitroprusside and isozyme-selective phosphodiesterase inhibitors on ADP-induced aggregation and cyclic nucleotide levels in human platelets. J Cardiovasc Pharmacol 1991; 18: 237– 242. 3 Barbier AJ, Lefebvre RA Effect of 3-isobutyl-1-methylxanthine and zaprinast on non-adrenergic non-cholinergic relaxation in the rat gastric fundus. Eur J Pharmacol 1992; 210: 315– 323. 4 Beavo JA, Reifsnyder DH Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150– 155. 5 Bergstrand H, Kristoffersson J, Lundquist B, Schumann A. Effects of antiallergic agents, Compound 48/80 and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases. Mol Pharmacol 1977; 13: 38– 43. 6 Broughton BJ, Chaplen P, Knowles P, et al. Antiallergic activity of 2-phenyl-8-azapurin-6-ones. J Med Chem 1975; 18: 1117– 1122. 7 Brunkhorst, D and der Leyen, H, Meyer W, Nigbur R, Schmidt-Schumacher C, Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 C1, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 1989; 339: 575– 583. 8 Burke-Wolin T, Abate CJ, Wolin MS, Gurtner GH Hydrogen peroxide-induced pulmonary vasodilation: role of guanosine 3′,5′-cyclic monophosphate. Am J Physiol 1991; 261: L393– L398. 9 Burns F, Rodger IW, Pyne JN The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung. Biochem J 1992; 283: 487– 491. 10 Bush PA, Aronson WJ, Buga GM, Rajfer J, Ignarro LJ Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 1992; 147: 1650– 1655. 11 Clemo HF, Feher JJ, Baumgarten CM Modulation of rabbit ventricular cell volume and Na+/K+/2Cl- cotransport by cGMP and atrial natriuretic factor. J Gen Physiol 1992; 100: 89– 114. 12 Dundore RL, Pratt PF, Hallenbeck WD, Wassey ML, Silver PJ, Buchholz RA Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats. Eur J Pharmacol 1990; 185: 91– 97. 13 Dundore RL, Pratt PF, O'Connor B, Buchholz RA, Pagani ED Nω-nitro-1-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast. Eur J Pharmacol 1991; 200: 83– 87. 14 Dundore RL, Habeeb PG, Pratt PF, Becker LT, Clas DM, Buchholz RA Differential hymodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats. J Cardiovasc Pharmacol 1992; 19: 937– 944. 15 Frodsham G, Jones RB Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle. Eur J Pharmacol 1992; 211: 383– 391. 16 Gibson A, Mirzazadeh S. N-methylhydroxylamine inhibits and M & B 22,948 potentiates relaxations of the mouse anococcygeus to non-adrenergic, non-cholinergic field stimulation and to nitrovasodilator drugs. Brit J Pharmacol 1989; 96: 637– 644. 17 Gillespie PG, Beavo JA Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M & B 22,948. Mol Pharmacol 1989; 36: 773– 781. 18 Gräser T, Vanhoutte PM Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP. Am J Physiol 1991; 261: H1769– H1777. 19 Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT, Silver PJ Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 1989; 249: 394– 400. 20 Haynes, J Jr and Kithas, PA, Taylor AE, Strada SJ Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am J Physiol 1991; 262: H487– H492. 21 Hoey M, Houslay MD Identification and selective inhibition of four distinctive soluble forms of cyclic nucleotide phosphodiesterase activity from kidney. Biochem Pharmacol 1990; 40: 193– 202. 22 Holbrook M, Coker SJ Effects of zaprinast and rolipram on platelet aggregation and arrythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Brit J Pharmacol 1991; 103: 1973– 1979. 23 Iwatsuki K, Horiuchi A, Ren L-M, Chiba S. Effects of the cyclic nucleotide phosphodiesterase inhibitors, rolipram, 3-isobutyl-l-methylxanthine, amrinone and zaprinast, on pancreatic exocrine secretion in dogs. Eur J Pharmacol 1991; 209: 63– 68. 24 Komas N, Lugnier C, Stoclet J-C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Brit J Pharmacol 1991; 104: 495– 503. 25 Komas N, Le Bee A, Stoclet J-C, Lugnier C. Cardiac cGMP-stimulated cyclic nucleotide phosphodiesterases: effects of cGMP analogues and drugs. Eur J Pharmacol 1991; 206: 5– 13. 26 Lee KC, Canniff PC, Hamel DW, et al. Comparative hemodynamic and renal effects of the low Km cGMP phosphodiesterase inhibitors cicletanine and zaprinast in anesthetized dogs. Drug Dev Res 1991; 23: 127– 144. 27 Leroy MJ, Cedrin I, Breuiller M, Giovagrandi Y, Ferre F. Correlation between selective inhibition of the cyclic nucleotide phosphodiesterases and the contractile activity in human pregnant myometrium near term. Biochem Pharmacol 1989; 38: 9– 15. 28 Lugnier C, Schini VB Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 1990; 39: 75– 84. 29 Mahomedy YA, Cowling CGD, Boeree B. A comparison of the effects of orally administered M & B 22,948 (zaprinast) and placebo on changes in ventilatory function in patients with exercise-induced bronchial asthma: A pilot study. Current Ther Res 1986; 40: 750– 760. 30 Martin W, Morgan RO, Smith JA, White DG Atriopeptin II-induced relaxation of rabbit aorta is potentiated by M & B 22,948 but not blocked by haemoglobin. Brit J Pharmacol 1986; 89: 557– 561. 31 Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-dependent relaxing factor. J Pharmacol Exp Ther 1986; 237: 539– 547. 32 Mathew R, Omar HA, Cherry PD, Gewitz MH, Wolin MS Role of cGMP mechanisms in response of rat pulmonary arteries to hypoxia. Am J Physiol 1992; 263: H141– H146. 33 Maurice DH, Haslam RJ Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671– 681. 34 McMahon EG, Palomo MA, Mehta P, Olins GM Depressor and natriuretic effects of M & B 22,948, a guanosine cyclic 3′,5′-monophosphate-selective phosphodiesterase inhibitor. J Pharmacol Exp Ther 1989; 252: 1000– 1005. 35 Merkel LA, Rivera LM, Perrone MH, Lappe RW In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur J Pharmacol 1992; 216: 29– 35. 36 Meyer, JD Jr and Huxley, VH Capillary hydraulic conductivity is elevated by cGMP-dependent vasodilators. Circ Res 1992; 70: 382– 391. 37 Moritoki H, Yoshikawa T, Hisayama T, Takeuchi S. Possible mechanism of age-associated reduction of vascular relaxation caused by atrial natriuretic peptide. Eur J Pharmacol 1992; 210: 61– 68. 38 Murray KJ, England PJ Inhibitors of cyclic nucleotide phosphodiesterase as therapeutic agents. Biochem Soc Trans 1992; 20: 460– 464. 39 Novak P, Walker R, Stacy DL, Rimele T. Antihypertensive effects of cAMP-(rolipram) and cGMP-(zaprinast) phosphodiesterase inhibitors after pretreatment with Nω-nitro-L-arginine (L-NNA). FASEB J 1991; 5: A1574. 40 Pagani ED, Buchholz RA, Silver PJ Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. Bas Res Cardiol 1992; 87(S1): 73– 86. 41 Pan X, Sauro MD, Coffey RG, Fitzpatrick DF, Krzanowski JJ, Poison JB Effect of cyclic nucleotide phosphodiesterase (PDE) inhibitors on proliferation of A10 cells. FASEB J 1991; 5: 1592. 42 Pan X, Coffey RG, Fitzpatrick DF, et al. Effects of vinpocetine and zaprinast on the proliferation of A10 cells. FASEB J 1992; 6: A1846. 43 Pang DC Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug development. Drug Dev Res 1988; 12: 85– 92. 44 Rapoport RM, Shraf M, Murad F. Effects of melittin on endotheilium-dependent relaxation and cyclic GMP levels in rat aorta. Circ Res 1989; 64: 463– 473. 45 Reiser J, Yeang Y, Warner JO The effect of zaprinast (M & B 22,948), an orally absorbed mast cell stabilizer), on exercise-induced asthma in children. Br J Dis Chest 1986; 80: 157– 163. 46 Rudd RM, Gellert AR, Studdy PR, Geddes DM Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). Br J Dis Chest 1983; 77: 78– 86. 47 Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet J-C. Role of cyclic AMP-and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. Biochem Pharmacol 1987; 36: 3965– 3972. 48 Silver PJ, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol 1988; 150: 85– 94. 49 Silver PJ, O'Connor B, Cumiskey WR, et al. Inhibition of low Km cGMP phosphodiesterases and Ca++-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmacol Exp Ther 1991; 257: 382– 391. 50 Silver PJ, Pagani ED, De Garavilla L, et al. Reversal of nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast. Eur J Pharmacol 1991; 199: 141– 142. 51 Simpson AWM, Reeves ML, Rink TJ Effects of SK & F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol 1988; 37: 2315– 2320. 52 Souness JE, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M & B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Brit J Pharmacol 1989; 98: 725– 734. 53 Souness JE, Diocee BK, Martin W, Moodie SA Pig aortic endothelial cell cyclic nucleotide phosphodiesterases. Biochem J 1990; 266: 127– 132. 54 Souness JE, Carter CM, Diocee BK, Hassall GA, Wood LJ, Turner NC Characterization of guinea-pig eosinophil phosphodiesterase activity. Biochem Pharmacol 1991; 42: 937– 945. 55 Torphy TJ, Undem BJ Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991; 46: 512– 523. 56 Trapani AJ, Smits GJ, McGraw DE, McMahon EG, Blaine EH Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmacol Exp Ther 1991; 258: 269– 274. 57 Ward SM, Dalziel HH, Bradley ME, et al. Involvement of cyclic GMP in non-adrenergic, non-cholinergic inhibitory neurotransmission in dog proximal colon. Brit J Pharmacol 1992; 107: 1075– 1082. 58 Watkins RW, Chintala MS, Sybertz EJ Effects of zaprinast on the coronary circulation in anesthetized dogs. FASEB J 1992; 6: A1579. 59 Watkins RW, Chiu PJS, Mundinger TO, McLeod R. Effect of zaprinast, sodium nitroprusside and 8-Br-cGMP on mean circulatory filling pressure in anesthetized SHR. FASEB J 1991; 5: A1582. 60 Weishaar RE, Cain MH, Bristol JA A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug sensitivity. J Med Chem 1985; 28: 537– 545. 61 Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 1986; 35: 787– 800. 62 Winquist RJ, Faison EP, Walsman SA, Schwartz K, Murad F, Rapoport RM Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci 1984; 81: 7661– 7664. 63 Wood LM, Owen DAA. A comparison of vasodilator activity of agents activating cyclic nucleotides with those inhibiting their metabolism in rabbit isolated ear artery. Brit J Pharmacol 1989; 96: 718– 724. 64 Yates DEB, Parkinson RP, Casson HCR, Sim MF Cardiovascular activity of phosphodiesterase inhibitors in the conscious dog. Brit J Pharmacol 1991; 102(suppl): 342P. Citing Literature Volume11, Issue4December 1993Pages 501-515 ReferencesRelatedInformation